Romiplostim is a thrombopoietin receptor agonist, but it is not a small molecule and not a conventional peptide. It is a peptibody: a recombinant Fc-peptide fusion protein built from two identical single-chain subunits, each carrying a human immunoglobulin G1 Fc domain covalently linked to a peptide that contains two thrombopoietin receptor-binding domains. The peptide does the receptor work. The Fc domain supplies the half-life. The protein is expressed in Escherichia coli.
What the receptor does
Endogenous thrombopoietin binds the c-Mpl receptor on megakaryocyte precursors in bone marrow, driving megakaryocyte maturation and platelet production. Romiplostim binds the same receptor and activates the same downstream signalling, but shares no sequence homology with endogenous thrombopoietin — a design choice intended to reduce the risk of neutralising antibody cross-reactivity.
The UK licensing picture
Romiplostim (Nplate) holds a UK marketing authorisation for the treatment of thrombocytopenia in immune thrombocytopenia (ITP) in adults who have responded insufficiently to corticosteroids, immunoglobulins or splenectomy. NICE technology appraisal TA221 recommends it as an option for adults with chronic immune (idiopathic) thrombocytopenic purpura in that group. It is supplied through the licensed medicines route, prescription only, with no consumer route.
What the evidence shows
The pivotal randomised trial, published by Kuter and colleagues in The Lancet in 2008, reported a durable platelet response in a substantially higher proportion of romiplostim-treated patients than of those on placebo. That is a human randomised dataset, which places the compound above the ceiling most research peptides never reach. The evidence is not unlimited: the UK product information carries monitoring requirements because of long-term thrombotic and bone-marrow reticulin signals observed in the class.
Why it belongs in the reference
Romiplostim is one of a small number of UK-licensed peptides whose peptide character is structural rather than obvious — a peptide engineered onto an antibody fragment rather than presented as a peptide therapeutic. Nothing here describes human use of an unlicensed material, and no protocol is implied: romiplostim is a prescription-only medicine, described here as published research.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.